(MDCO:Consolidated Issue Listed on NASDAQ Global Select )
Steven Steinhubl M.D., FACC
Global Vice President of Thrombosis, The Medicines Company
|Age||Total Calculated Compensation||This person is connected to 0 board members in 0 different organizations across 2 different industries.|
Dr. Steven R. Steinhubl, M.D., FACC has been Global Vice President of Thrombosis of Medicines Co. since February 2008. Dr. Steinhubl is responsible for the development programs for both cangrelor, an investigational antiplatelet agent, and Angiox(R) (bivalirudin) from the European headquarters in Zurich, Switzerland. Dr. Steinhubl joined Medicines Co. as Global Vice President, of Thrombosis. He has an extensive experience as a clinical trialist having served as a Principal ...
8 Sylvan WayPhone: 973-290-6000
Parsippany, New Jersey 07054
Board Members Memberships*There is no Board Members Memberships data available.
Education*There is no Education data available.
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
Total Compensation*There is no Total Compensation data available.
|Steven G. Anderson||Founder, Chairman, Chief Executive Officer and President|
|Robert L. Parkinson Jr.||Chairman, Chief Executive Officer and President|
Baxter International Inc.
|Andrew Philip Witty||Chief Executive Officer, Executive Director, Member of Corporate Administration & Transactions Committee and Member of Finance Committee|
|John C. Lechleiter Ph.D.||Chairman, Chief Executive Officer and President|
Eli Lilly and Company
|Albert D. Friesen Ph.D.||Founder, Chairman and Chief Executive Officer|
|C$180.0K||Compensation as of Fiscal Year 2013.|
Post a JobJobs
- Home, WA | Medicines CompanyPosted: Apr 14
- New Jersey | Medicines CompanyPosted: Mar 21
- New Jersey | Medicines CompanyPosted: Apr 14
- New Jersey | Medicines CompanyPosted: Apr 09